A study investigating a new form of insulin-deficient diabetes in children and young adults in Cameroon

Prospective study of non-Autoimmune insuliN-Deficient diabetes subtype in young individuals in sub-saharan Africa

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN15312527

Enrollment

595

Registered

2026-07-16

Start date

2026-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinically diagnosed type 1 diabetes, non-autoimmune insulin-deficient diabetes (NAID), autoimmune type 1 diabetes, diabetes heterogeneity in children and young adults Nutritional, Metabolic, Endocrine

Interventions

Eligible participants will be identified from the national Changing Diabetes in Children (CDiC) registry and through consecutive recruitment of newly diagnosed cases attending the Yaoundé Central Hosp

Eligibility

Sex/Gender

All

Age

1 Years to 25 Years

Inclusion criteria

Inclusion criteria: 1. Clinical diagnosis of type 1 diabetes made before 25 years of age 2. Diabetes duration less than 12 months at enrolment 3. Receiving insulin treatment only 4. Registered within the Changing Diabetes in Children (CDiC) programme in Cameroon 5. Able and willing to provide informed consent or assent with parental/legal representative consent where applicable Healthy controls: Age- and sex-matched individuals without diabetes and unrelated to diabetes participants

Exclusion criteria

Exclusion criteria: 1. Critically ill patients requiring urgent hospital admission or emergency intervention 2. Pregnant participants

Design outcomes

Primary

Measure	Time frame
Clinical and metabolic characteristics distinguishing NAID from autoimmune type 1 diabetes measured using islet autoantibody status (GADA, IA-2A, ZnT8A), random or stimulated C-peptide concentrations, clinical and anthropometric phenotyping, and pancreatic imaging measurements at baseline	—

Secondary

Measure	Time frame
Beta-cell function measured using C-peptide concentrations measured using direct electrochemiluminescence immunoassay on the 601 module of the Roche Cobas 8000 automated instrument (Roche Diagnostics, Manheim, Germany) at baseline, 6 months, 1 year, 2 years, and 3 years;Glycaemic control measured using HbA1c at baseline, 1 year, 2 years, and 3 years;Severe hypoglycaemia and diabetic ketoacidosis (DKA) episodes measured using self report at 6 months, 1 year, 2 years, and 3 years;Pancreatic shape, volume and architecture measured using a standardised MRI protocol at 6 months;Beta-cell function during a mixed meal tolerance test measured using direct electrochemiluminescence immunoassay on the 601 module of the Roche Cobas 8000 automated instrument (Roche Diagnostics, Manheim, Germany) at 6 months	—

Measure

Time frame

Beta-cell function measured using C-peptide concentrations measured using direct electrochemiluminescence immunoassay on the 601 module of the Roche Cobas 8000 automated instrument (Roche Diagnostics, Manheim, Germany) at baseline, 6 months, 1 year, 2 years, and 3 years;Glycaemic control measured using HbA1c at baseline, 1 year, 2 years, and 3 years;Severe hypoglycaemia and diabetic ketoacidosis (DKA) episodes measured using self report at 6 months, 1 year, 2 years, and 3 years;Pancreatic shape, volume and architecture measured using a standardised MRI protocol at 6 months;Beta-cell function during a mixed meal tolerance test measured using direct electrochemiluminescence immunoassay on the 601 module of the Roche Cobas 8000 automated instrument (Roche Diagnostics, Manheim, Germany) at 6 months

—

Countries

Cameroon

Contacts

Public ContactEmmanuel Gwan

emmagwan73@gmail.com+237 (0)673411724

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Aug 10, 2026